Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are untreated. Over the last several years, several targeted or small-molecule therapies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Tycel J., Bond, David, Takiar, Radihka, Kump, Karson, Kandarpa, Malalthi, Boonstra, Philip, Mayer, Tera Lynn, Nachar, Victoria, Wilcox, Ryan A., Carty, Shannon A., Karimi, Yasmin H., Nikolovska-Coleska, Zaneta, Kaminski, Mark S., Herrera, Alex F., Maddocks, Kami, Popplewell, Leslie, Danilov, Alexey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425679/
https://www.ncbi.nlm.nih.gov/pubmed/37013954
http://dx.doi.org/10.1182/bloodadvances.2023009992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425679/
https://www.ncbi.nlm.nih.gov/pubmed/37013954
http://dx.doi.org/10.1182/bloodadvances.2023009992

Ejemplares similares